Drug Pipeline

March 08, 2021

Will emerging variants make the leading vaccines less protective?

February 01, 2021

Opinion piece by MHE's Editorial Advisory Board Member and CEO of The Pharmacy Group, Perry Cohen. Perry discusses the response differences and vague similarities between the countries and addresses the continuous question, "What is the new normal?"

January 15, 2021

The industry is adjusting to the pandemic, but FDA approvals could dip this year. Several new drugs for atopic dermatitis may get the agency’s green light.

December 16, 2020

Pre-pandemic momentum helped keep the number of novel therapies approved by the FDA high, and then COVID-19 tested just how fast the pipeline could adjust and expand.

November 27, 2020

Results of APOLLO and REACH3 trials are scheduled for presentation at the American Society of Hematology meeting next month are expected to garner attention.

September 28, 2020

Negative results for semorinemab have deflated some of the hopes for a tau as a target, although a winning strategy Alzheimer's may involve hitting several targets at once, including tau.

August 23, 2020

FDA actions for the week ending August 21, 2020, include a hearing set for a drug that could limit weight gain often associated with treatment for serious mental illness.

August 16, 2020

Actions from FDA this week include approval of a second targted treatment for a Duchenne muscular dystrophy mutation, and filings in COVID-19 and blood disorders.

August 02, 2020

In a busy week, FDA approved ground-breaking therapies in hematologic cancers and issued Orphan Drug designations in areas of significant unmet need.

July 31, 2020

Potential agents to battle inflammation and other processes move through development pipeline.